M Busch

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Oversight and monitoring of blood safety in the United States
    M Busch
    Research and Scientific Services, Blood Centers of the Pacific, San Francisco, CA 94118 4496, USA
    Vox Sang 77:67-76. 1999
  2. ncbi A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 45:254-64. 2005
  3. ncbi Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003
    M P Busch
    Blood Systems Research Institute, San Francisco, California, USA
    Transfusion 45:492-9. 2005
  4. ncbi Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Michael P Busch
    Blood Systems Research Institute, University of California, 270 Masonic Avenue, San Francisco, CA 94904, USA
    Transfus Clin Biol 11:26-32. 2004
  5. ncbi Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 46:469-75. 2006
  6. ncbi Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 45:1853-63. 2005
  7. ncbi Current and emerging infectious risks of blood transfusions
    Michael P Busch
    Blood Centers of the Pacific, and University of California, San Francisco, 270 Masonic Ave, San Francisco, CA 94118, USA
    JAMA 289:959-62. 2003
  8. ncbi Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients
    M P Busch
    Blood Centers of the Pacific, San Francisco, CA 94118, United States
    Transfus Clin Biol 8:200-6. 2001
  9. ncbi False-negative testing errors in routine viral marker screening of blood donors. For the Retrovirus Epidemiology Donor Study
    M P Busch
    Division of Research and Scientific Services, Blood Centers of the Pacific Irwin Center, San Francisco, CA 94118, USA
    Transfusion 40:585-9. 2000
  10. ncbi Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays:justification and rational implementation
    L H Tobler
    Blood Centers of the Pacific, Irwin Center, San Francisco, California 94118, USA
    Transfusion 40:15-24. 2000

Detail Information

Publications99

  1. ncbi Oversight and monitoring of blood safety in the United States
    M Busch
    Research and Scientific Services, Blood Centers of the Pacific, San Francisco, CA 94118 4496, USA
    Vox Sang 77:67-76. 1999
    ....
  2. ncbi A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 45:254-64. 2005
    ....
  3. ncbi Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003
    M P Busch
    Blood Systems Research Institute, San Francisco, California, USA
    Transfusion 45:492-9. 2005
    ..A study was conducted to evaluate sensitivities of WNV screening and supplemental NAT assays first employed in 2003...
  4. ncbi Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Michael P Busch
    Blood Systems Research Institute, University of California, 270 Masonic Avenue, San Francisco, CA 94904, USA
    Transfus Clin Biol 11:26-32. 2004
    ..Finally it will address the cost effectiveness of incorporation of HBV DNA detection into HBV screening and NAT testing algorithms...
  5. ncbi Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 46:469-75. 2006
    ..Factors associated with resolution of viremia are not well defined. Implementation of routine nucleic acid testing (NAT) of blood donors has yielded a large data set for analysis of demographic correlates of resolved viremia...
  6. ncbi Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 45:1853-63. 2005
    ..We compared these assays with respect to detection of RNA in early HIV and HCV infection...
  7. ncbi Current and emerging infectious risks of blood transfusions
    Michael P Busch
    Blood Centers of the Pacific, and University of California, San Francisco, 270 Masonic Ave, San Francisco, CA 94118, USA
    JAMA 289:959-62. 2003
  8. ncbi Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients
    M P Busch
    Blood Centers of the Pacific, San Francisco, CA 94118, United States
    Transfus Clin Biol 8:200-6. 2001
    ..Thus, the findings from studies of HCV among donors and blood product recipients have yielded and should continue to provide important insights into HCV pathogenesis leading to novel diagnostic, therapeutic and vaccination strategies...
  9. ncbi False-negative testing errors in routine viral marker screening of blood donors. For the Retrovirus Epidemiology Donor Study
    M P Busch
    Division of Research and Scientific Services, Blood Centers of the Pacific Irwin Center, San Francisco, CA 94118, USA
    Transfusion 40:585-9. 2000
    ..Although the false-negative testing error rate has been estimated at 0.1 to 1 percent on the basis of proficiency studies, it has not previously been measured in routine donor screening...
  10. ncbi Lookback on donors who are repeatedly reactive on first-generation hepatitis C virus assays:justification and rational implementation
    L H Tobler
    Blood Centers of the Pacific, Irwin Center, San Francisco, California 94118, USA
    Transfusion 40:15-24. 2000
    ..The purpose of this study was to explore strategies to minimize the number of unwarranted consignee notifications resulting from hepatitis C virus (HCV) first-generation (single-antigen) enzyme immunoassay (EIA 1.0) targeted lookback...
  11. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..Quantitative analysis of preseroconversion replication rates of HIV is useful for projecting the yield and predictive value of assays targeting primary HIV infection...
  12. ncbi Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates
    Kimberly Page-Shafer
    University of California, San Francisco, California, USA
    J Clin Microbiol 46:499-506. 2008
    ..4; 95% CI, 28.0 to 39.9). This study demonstrates the value of applying a cross-sectional screening strategy to detect acute HCV infections and to estimate HCV incidence...
  13. ncbi Persistence of primary drug resistance among recently HIV-1 infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, San Francisco, California 94141-9100, USA
    AIDS 18:1683-9. 2004
    ..Surveillance and clinical detection of primary resistance is feasible in the first year of infection...
  14. ncbi Surveillance of the genetic variation in incident HIV, HCV, and HBV infections in blood and plasma donors: implications for blood safety, diagnostics, treatment, and molecular epidemiology
    Eric Delwart
    Blood Systems Research Institute, and Department of Laboratory Medicine, University of California, San Francisco, California, USA
    J Med Virol 78:S30-5. 2006
    ..A systematic program is proposed for the genetic characterization of viral genomes in donors with incident HIV, HCV, or HBV infections...
  15. ncbi Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection
    S A Stranford
    Department of Medicine, University of California, San Francisco, CA 94143; Blood Centers of the Pacific, San Francisco, CA 94118, USA
    Proc Natl Acad Sci U S A 98:597-602. 2001
    ....
  16. ncbi Virus and antibody dynamics in acute west nile virus infection
    Michael P Busch
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    J Infect Dis 198:984-93. 2008
    ..The dynamics of the early stages of West Nile virus (WNV) infection can be assessed by follow-up studies of viremic blood donors...
  17. ncbi Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms
    Steven H Kleinman
    Blood Systems Research Institute, San Francisco, California, USA
    Transfusion 46:695-702. 2006
    ....
  18. ncbi Risk factors for incident HIV infection among anonymous HIV testing site clients in Santos, Brazil: 1996-1999
    Katia Alves
    Blood Centers of the Pacific, San Francisco, California, U.S.A
    J Acquir Immune Defic Syndr 32:551-9. 2003
    ..Results from this study will help to target appropriate prevention strategies directed toward at-risk populations in Santos...
  19. ncbi Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection
    Philip J Norris
    Blood Systems Research Institute, San Francisco, California 94118, USA
    AIDS Res Hum Retroviruses 22:757-62. 2006
    ..Cytokine alterations occurred within 7 days of detectable HIV-1 viremia, emphasizing the need to study the earliest events of infection...
  20. ncbi Intermittent low-level viremia in very early primary HIV-1 infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 39:133-7. 2005
    ..It is not known if blood is infectious during this period; however, given the low viral concentrations and transient nature of the observed viremic "blips," the risk of infectivity can be assumed to be small...
  21. ncbi Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors
    Daisy M Machado
    Blood Centers of the Pacific, San Francisco, California 94118, USA
    AIDS 16:113-9. 2002
    ....
  22. ncbi Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing
    Michael P Busch
    Blood Systems Research Institute, San Francisco, USA
    N Engl J Med 353:460-7. 2005
    ..These data support the use of targeted nucleic acid amplification testing of individual donations in high-prevalence regions, a strategy that was implemented successfully in 2004...
  23. ncbi Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients
    Farnaz Vahidnia
    Department of Epidemiology, Blood Systems Research Institute, San Francisco, CA, USA
    J Infect Dis 205:1436-42. 2012
    ..Few studies describe predictors of acute GBV-C infection following transfusion in HIV-infected patients...
  24. ncbi Estimating blood donor loss due to the variant CJD travel deferral
    Edward L Murphy
    University of California and Blood Centers of the Pacific, San Francisco, California, USA
    Transfusion 44:645-50. 2004
    ..The FDA recommended new travel deferrals in May 2002 to prevent the potential transmission of variant CJD (vCJD). The predicted impact of such deferrals on the blood supply was controversial...
  25. ncbi The cost-effectiveness of screening the U.S. blood supply for West Nile virus
    Brian Custer
    Blood Systems Research Institute, University of California, San Francisco, CA 94118 4417, USA
    Ann Intern Med 143:486-92. 2005
    ..The spread of West Nile virus across North America and evidence of transmission by transfusion prompted the U.S. Food and Drug Administration to encourage the development of methods to screen the blood supply...
  26. ncbi Performance of a transcription-mediated-amplification HIV-1 RNA assay in pooled specimens
    Nicola M Zetola
    Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, United States
    J Clin Virol 40:68-70. 2007
    ..Very limited data exist on the comparative performance of nucleic acid amplification tests (NATs) for the screening of pooled specimens for acute human immunodeficiency virus (HIV) infection...
  27. ncbi Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    J Infect Dis 190:251-6. 2004
    ..The pol RC value of 43% may represent a threshold below which HIV-1 has lowered virulence and is less able to deplete CD4(+) T cell counts...
  28. ncbi HIV RNA testing in the context of nonoccupational postexposure prophylaxis
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, CA 94110, USA
    J Infect Dis 190:598-604. 2004
    ..The specificity and positive predictive value of human immunodeficiency virus (HIV) RNA assays have not been evaluated in the setting of postexposure prophylaxis (PEP)...
  29. ncbi Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection
    C Bradley Hare
    Positive Health Program, University of California, San Francisco, San Francisco, CA, USA
    Clin Infect Dis 42:700-8. 2006
    ....
  30. ncbi Emerging infections in transfusion medicine
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA
    Clin Lab Med 24:797-823, viii. 2004
    ....
  31. ncbi Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing for West Nile virus: analysis of 2003 data to inform 2004 decision making
    Brian Custer
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 44:1547-54. 2004
    ..Strategies were investigated for the application of limited ID-NAT capacity in 2004...
  32. ncbi Seroconversion following nonoccupational postexposure prophylaxis against HIV
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, California, USA
    Clin Infect Dis 41:1507-13. 2005
    ..We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP...
  33. ncbi Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains
    Eric L Delwart
    Blood Systems Research Institute, San Francisco 94118, California, USA
    AIDS Res Hum Retroviruses 19:1065-70. 2003
    ..The frequency of genetically confirmed non-subtype-B HIV infection in a geographically dispersed group of infected U.S. blood donors in 1977-2000 was therefore 2.0% (6/312)...
  34. ncbi Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy
    Hiroyu Hatano
    San Francisco General Hospital, Building 80, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA
    J Virol 83:329-35. 2009
    ..This confirms the failure to eradicate the virus, even in these unique individuals who are able to reduce plasma viremia to very low levels without antiretroviral therapy...
  35. ncbi Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection
    Kimberly Page
    Department of Epidemiology and Biostatistics, University of California, San Francisco, 50 Beale St, Ste 1200, San Francisco, CA 94105, USA
    J Infect Dis 200:1216-26. 2009
    ..Hepatitis C virus (HCV) infection, clearance, and reinfection are best studied in injection drug users (IDUs), who have the highest incidence of HCV and are likely to represent most infections...
  36. ncbi Dengue viremia in blood donors from Honduras, Brazil, and Australia
    Jeffrey M Linnen
    Gen Probe, Inc, San Diego, California, USA
    Transfusion 48:1355-62. 2008
    ..Documented transfusion transmission of West Nile virus raised concern regarding transfusion-transmitted DENV...
  37. ncbi Time trends in primary HIV-1 drug resistance among recently infected persons
    Robert M Grant
    Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
    JAMA 288:181-8. 2002
    ..Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy...
  38. ncbi Cost-effectiveness of screening the US blood supply for Trypanosoma cruzi
    Maria Agapova
    Blood Systems Research Institute, San Francisco, California 94117, USA
    Transfusion 50:2220-32. 2010
    ..Component-specific strategies are based on screening platelet-containing donations...
  39. ncbi Hepatitis C virus seroconversion among young injection drug users: relationships and risks
    Judith A Hahn
    Department of Epidemiology, University of California, San Francisco, 94110, USA
    J Infect Dis 186:1558-64. 2002
    ..Interventions to reduce HCV transmission must recognize the importance of relationships on injecting risk...
  40. ncbi Hepatitis C virus prevalence and clearance among US blood donors, 2006-2007: associations with birth cohort, multiple pregnancies, and body mass index
    Edward L Murphy
    University of California, San Francisco, CA, USA
    J Infect Dis 202:576-84. 2010
    ..During the period 1992-1993, the prevalence of hepatitis C virus (HCV) antibodies (anti-HCV) among US blood donors was 0.36%, but contemporary data on the prevalence of antibody to HCV and the prevalence of HCV RNA are lacking...
  41. ncbi Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals
    Hiroyu Hatano
    Department of Medicine, University of California, San Francisco, California, USA
    AIDS 24:2535-9. 2010
    ..HAART can effectively reduce plasma HIV RNA levels to below the level of detection in most HIV-infected patients. The degree to which residual low-level viremia persists during HAART remains unclear...
  42. ncbi Estimating past hepatitis C infection risk from reported risk factor histories: implications for imputing age of infection and modeling fibrosis progression
    Peter Bacchetti
    Box 0560, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA 94143, USA
    BMC Infect Dis 7:145. 2007
    ..We sought to examine the accuracy of such imputation and implications for modeling factors that influence progression rates...
  43. ncbi Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion
    S Schwarcz
    San Francisco Department of Public Health, San Francisco, CA 94102, USA
    Am J Epidemiol 153:925-34. 2001
    ..6% per year and remained steady between 1989 and 1998 (odds ratio per year = 0.99, 95% CI: 0.92, 1.1). During a dramatic, 10-year decline in seroprevalence of HIV infection, the incidence of HIV infection remained remarkably stable...
  44. ncbi Immune response to blood transfusion invery-low-birthweight infants
    J Wang-Rodriguez
    University of California, San Diego, Medical Center, Hillcrest, San Diego, California, USA
    Transfusion 40:25-34. 2000
    ..Allogeneic blood transfusion is common in the treatment of neonatal anemia of prematurity or anemia due to multiple phlebotomies. The immune response of neonates to passenger leukocytes from allogeneic red cells was investigated...
  45. ncbi Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients
    W Lawrence Drew
    University of California, San Francisco, Mount Zion Medical Center, California 94115, USA
    Transfusion 43:1351-7. 2003
    ....
  46. ncbi A case-control study of factors associated with resolution of hepatitis C viremia in former blood donors (CME)
    Leslie H Tobler
    Blood Systems Research Institute, San Francisco, California, USA
    Transfusion 50:1513-23. 2010
    ..We report a case-control study of factors associated with HCV resolution...
  47. ncbi Impact of HCV 3.0 EIA relative to HCV 2.0 EIA on blood-donor screening
    Leslie H Tobler
    Blood Centers of the Pacific, Irwin Center, San Francisco, California 94118, USA
    Transfusion 43:1452-9. 2003
    ..0 EIA; the second study evaluated the differential performance of HCV 3.0 EIA in plasma donors acutely infected with HCV, identified during routine Abbott HCV 2.0 EIA and HCV NAT (using Roche Ampliscreen plate assay) donor screening...
  48. ncbi Quantitation of HTLV-I and II proviral load using real-time quantitative PCR with SYBR Green chemistry
    Tzong-Hae Lee
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    J Clin Virol 31:275-82. 2004
    ..The sensitivity and high dynamic range allow determination of a broad range of HTLV-I/II proviral load in clinical subjects. This assay will facilitate the study of the relationship between proviral load and pathogenesis...
  49. ncbi West Nile virus infections projected from blood donor screening data, United States, 2003
    Michael P Busch
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Emerg Infect Dis 12:395-402. 2006
    ..In addition to preventing transfusion-transmitted WNV infection, donor screening can serve as a tool to monitor seasonal incidence in the general population...
  50. ncbi Evaluation of a new enzyme-linked immunosorbent assay for detection of Chagas antibody in US blood donors
    Leslie H Tobler
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 47:90-6. 2007
    ..An anonymized preclinical study of a prototype T. cruzi lysate-based enzyme-linked immunosorbent assay (ELISA) developed by Ortho-Clinical Diagnostics was conducted...
  51. ncbi Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors
    Anne M Guiltinan
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Am J Epidemiol 167:743-50. 2008
    ..High rates of mortality from drug/alcohol and trauma/suicide causes are likely due to lifestyle factors and may be at least partially preventable...
  52. ncbi Phylogenetic analysis of WNV in North American blood donors during the 2003-2004 epidemic seasons
    Belinda L Herring
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Virology 363:220-8. 2007
    ..Amino acid mutations associated with newly expanding genetic variants reflect either selectively neutral mutational drift and/or mutations providing replicative advantages over the previously dominant forms of WNV...
  53. ncbi Transfusion-transmitted viral infections: building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis
    Michael P Busch
    Blood Systems Research Institute, University of California at San Francisco, California 94118, USA
    Transfusion 46:1624-40. 2006
  54. ncbi Identification of specificities of antibodies against human leukocyte antigens in blood donors
    Robert O Endres
    Blood Systems Research Institute, San Francisco, California 85282, USA
    Transfusion 50:1749-60. 2010
    ..Blood centers are implementing TRALI risk reduction strategies based on screening apheresis donors for antibodies to human leukocyte antigens (HLA)...
  55. ncbi Tregs control the development of symptomatic West Nile virus infection in humans and mice
    Marion C Lanteri
    Blood Systems Research Institute, San Francisco, California 94118, USA
    J Clin Invest 119:3266-77. 2009
    ..Together, these results suggest that higher levels of peripheral Tregs after infection protect against severe WNV disease in immunocompetent animals and humans...
  56. ncbi Associations between West Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening
    Brian Custer
    Blood Systems Research Institute, University of California, San Francisco, USA
    Transfusion 49:278-88. 2009
    ..Little data are available on subsequent manifestations of WNV-specific disease outcomes in viremic donors...
  57. ncbi Long-term in vitro reactivity for human leukocyte antigen antibodies and comparison of detection using serum versus plasma
    Philip J Norris
    Blood Systems Research Institute, University of California, San Francisco, USA
    Transfusion 49:243-51. 2009
    ..Serum is the manufacturer's recommended sample, but plasma may be easier to obtain for studies of HLA antibody prevalence and TRALI case investigations...
  58. ncbi Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection
    Bhupat D Rawal
    Blood Centers of the Pacific, San Francisco, California 94118, USA
    J Acquir Immune Defic Syndr 33:349-55. 2003
    ..These results support the potential use of the Vironostika-LS EIA for detection of recent HIV-1 infections for incidence projections and for other epidemiologic, clinical, and molecular surveillance applications...
  59. ncbi Blood transfusion is associated with donor leukocyte microchimerism in trauma patients
    Garth H Utter
    Department of Surgery, University of California, Davis, Medical Center, Blood Centers of the Pacific, San Francisco, California 95817, USA
    J Trauma 57:702-7; discussion 707-8. 2004
    ..Because the median time from transfusion to sampling for PCR analysis was not longer in the group without microchimerism, it is unlikely microchimerism is due merely to failure of the recipient to clear transfused donor leukocytes...
  60. ncbi Interferon and interferon-induced chemokine expression is associated with control of acute viremia in West Nile virus-infected blood donors
    Leslie H Tobler
    University of California, San Francisco, CA 94118, USA
    J Infect Dis 198:979-83. 2008
    ..These findings suggest that IFN-mediated innate immunity plays a key role in initial control of WNV replication...
  61. ncbi Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis
    W Lawrence Drew
    Mount Zion Medical Center, University of California, San Francisco, CA 94115, USA
    J Infect Dis 186:114-7. 2002
    ..These rates were similar among case patients and control subjects and were similar by risk group. The CMV gB2 genotype is not a major determinant of retinitis pathogenicity but appears to be highly prevalent among HIV-infected patients...
  62. ncbi Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients
    William Reed
    Blood Systems Research Institute, San Francisco, CA 94118, USA
    Semin Hematol 44:24-31. 2007
    ....
  63. ncbi The consequences of temporary deferral on future whole blood donation
    Brian Custer
    Blood Systems Research Institute, 270 Masonic Avenue, San Francisco, CA 94118, USA
    Transfusion 47:1514-23. 2007
    ..The consequences of temporary deferral are not well understood. This study sought to investigate blood donor return after deferral expiration...
  64. ncbi The TNF (-308A) polymorphism is associated with microchimerism in transfused trauma patients
    Ryan M Gill
    Department of Laboratory Medicine, University of California, San Francisco, USA
    Blood 111:3880-3. 2008
    ..Hence predisposing genetic factors may explain, in part, why only a subset of trauma patients develops transfusion-associated microchimerism...
  65. ncbi Clinical investigation of posttransfusion Kidd blood group typing using a rapid normalized quantitative polymerase chain reaction
    Lani Montalvo
    Blood Systems Research Institute, Blood Centers of the Pacific, San Francisco, California 94118, USA
    Transfusion 44:694-702. 2004
    ..The assay performs well in the clinical setting. With further study, and inclusion of other blood group systems, this may become an important supplemental technique for selected patients in the immunohematology reference laboratory...
  66. ncbi Microchimerism in transfused trauma patients is associated with diminished donor-specific lymphocyte response
    Garth H Utter
    Department of Surgery, University of California, Davis, Medical Center, Sacramento, California 95817, USA
    J Trauma 58:925-31; discussion 931-2. 2005
    ..The blood donor associated with this diminished alloantigenic lymphocyte response may be the source of microchimeric cells present in the recipient...
  67. ncbi Persistence of West Nile virus-specific antibodies in viremic blood donors
    Harry E Prince
    Focus Diagnostics, Cypress, California, USA
    Clin Vaccine Immunol 14:1228-30. 2007
    ..At 1-year of follow-up, 17% of the donors (n = 23) were positive for WNV IgM, 57% were positive for WNV IgA, and 100% were positive for WNV IgG...
  68. ncbi Enhanced ascertainment of microchimerism with real-time quantitative polymerase chain reaction amplification of insertion-deletion polymorphisms
    Tzong Hae Lee
    Blood Systems Research Institute, San Francisco, California 94118, USA
    Transfusion 46:1870-8. 2006
    ..To address this, a panel of 12 MC assays based on insertion-deletion (InDel) polymorphisms had been optimized...
  69. ncbi Microchimerism decades after transfusion among combat-injured US veterans from the Vietnam, Korean, and World War II conflicts
    Garth H Utter
    Department of Surgery, University of California, Davis, Medical Center, Sacramento, California 95817, USA
    Transfusion 48:1609-15. 2008
    ..The purpose of this study was to determine how long transfusion-associated MC lasts after traumatic injury...
  70. ncbi Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection
    Robin Biswas
    Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, Maryland, USA
    Transfusion 43:788-98. 2003
    ..Single-sample NAT would increase yield by 13 to 15 units per 107 donations over pooled-sample NAT and newer HBsAg assays and by 35 to 50 units per 107 donations over currently licensed HBsAg assays...
  71. ncbi Dynamics of viremia in early hepatitis C virus infection
    Simone A Glynn
    Westat, Rockville, Maryland, USA
    Transfusion 45:994-1002. 2005
    ..Animal inoculation studies are in progress to evaluate if transfusion of low-level viremic plasma can transmit HCV infection...
  72. ncbi Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV
    Eishiro Mizukoshi
    Immunology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda 20892, USA
    J Infect Dis 198:203-12. 2008
    ..To identify immunological correlates for this apparent protection, we studied HCV-specific immune responses in long-term IDUs (duration, >10 years)...
  73. ncbi Effect of a national disaster on blood supply and safety: the September 11 experience
    Simone A Glynn
    Westat, Rockville, Md 20850 2062, USA
    JAMA 289:2246-53. 2003
    ..An understanding of characteristics of blood donors donating in times of crisis may help predict blood supply safety and donor return patterns...
  74. ncbi CMV DNA is rarely detected in healthy blood donors using validated PCR assays
    John D Roback
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Transfusion 43:314-21. 2003
    ..NAT of blood components for CMV DNA has been proposed to further reduce the risks of TT-CMV. However, large-scale studies to determine the utility of validated CMV NAT assays for donor screening have not been reported...
  75. ncbi Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening
    Steven H Kleinman
    Westat, Rockville, Maryland, USA
    Transfusion 43:696-704. 2003
    ..An estimate of the rate of HBV DNA-positive, anti-HBc-positive units is important for evaluating the need for anti-HBc donor screening, especially in the context of HBV NAT...
  76. ncbi Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California and the Blood Centers of the Pacific, USA
    Transfusion 43:309-13. 2003
    ..To explain this residual risk, evidence of cell-free viremia was sought in seroconverting and seroprevalent blood donors and seroconverting transfusion recipients by means of a plasma-based assay for CMV DNA...
  77. ncbi Fluctuation of HCV viral load before seroconversion in a healthy volunteer blood donor
    Chyang T Fang
    Jerome H. Holland Laboratory for the Biomedical Sciences, American Red Cross Biomedical Research and Development, 15601 Crabbs Branch Way, Rockville, MD 20855, USA
    Transfusion 43:541-4. 2003
    ....
  78. ncbi Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection
    David M Asmuth
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, University of California Davis Medical Center, 4150 V Street, Suite 6200 PSSB, Sacramento, CA 95817, USA
    Transfusion 43:451-8. 2003
    ....
  79. ncbi Impact of changes in viral marker screening assays
    Usha K Sharma
    Westat, Rockville, Maryland, USA
    Transfusion 43:202-14. 2003
    ..Before considering changes in screening tests, blood centers should be aware of, and evaluate, the potential impact on donor loss...
  80. ncbi HIV seroconverting donors delay their return: screening test implications
    George B Schreiber
    Westat, Rockville, Maryland, USA
    Transfusion 42:414-21. 2002
    ..One possible explanation is that HIV seroconverting donors delay their return because of the recent practice of risk behaviors and/or signs and symptoms associated with primary infection...
  81. ncbi Use of laboratory tests and clinical symptoms for identification of primary HIV infection
    Frederick M Hecht
    Positive Health Program HIV Section at San Francisco General Hospital, tUniversity of California at San Francisco, 94110, USA
    AIDS 16:1119-29. 2002
    ..False-positive results can be reduced through duplicate testing and considering tests < 5000 copies/ml as indeterminate results requiring additional testing. p24 antigen was more specific than HIV-1 RNA testing but less sensitive...
  82. ncbi Clinical significance of nondiscriminated reactive results with the Chiron Procleix HIV-1 and HCV assay
    Joan D McAuley
    Blood Systems Laboratory and Arizona State University, Tempe, 85282, USA
    Transfusion 44:91-6. 2004
    ..This study was designed to determine the clinical significance of NDR results...
  83. ncbi Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus
    Michael K Hourfar
    Institute of Transfusion and Immunohematology, German Red Cross Baden Württemberg Hessen, Johann Wolfgang Goethe University, Frankfurt, Germany
    Transfusion 48:1558-66. 2008
    ..In 1997, nucleic acid amplification technique (NAT)-testing was introduced at the German Red Cross (GRC) blood donor services to reduce this diagnostic window period (WP)...
  84. ncbi HCV viral load in anti-HCV-reactive donors and infectivity for their recipients
    Eva A Operskalski
    Transfusion Viruses Program, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9560, USA
    Transfusion 43:1433-41. 2003
    ..This is important for considerations about assay sensitivity, use of minipool versus single-donation testing, and continued use of serologic testing...
  85. ncbi Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors
    Harry E Prince
    Focus Diagnostics, Cypress, CA 90630, USA
    J Clin Microbiol 43:4316-20. 2005
    ..Thus, unlike some other flavivirus infections, WNV infection is not characterized by a relatively rapid disappearance of virus-specific IgA...
  86. ncbi Prevalence of HIV-1 in blood donations following implementation of a structured blood safety policy in South Africa
    Anthon du P Heyns
    South African National Blood Service, Weltevreden Park, South Africa
    JAMA 295:519-26. 2006
    ..The prevalence of HIV-1 in blood donations increased to 0.26% (1:385) in 1998, indicating that a significant number of window-period infective units were entering the blood supply (risk 3.4/100,000)...
  87. ncbi Nucleic acid amplification testing for diagnosis of acute HIV infection: has the time come?
    Michael P Busch
    AIDS 19:1317-9. 2005
  88. ncbi Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil
    Claudia C Barreto
    , , , Brazil
    J Acquir Immune Defic Syndr 41:338-41. 2006
    ..Although HIV-1 subtype B remains predominant, subtypes F and C and recombinant forms are present in substantial proportions in infected donors...
  89. ncbi New strategies for blood donor screening for hepatitis B virus: nucleic acid testing versus immunoassay methods
    Mary C Kuhns
    Abbott Diagnostics, Abbott Park, Illinois 60064, USA
    Mol Diagn Ther 10:77-91. 2006
    ..Each country will need to develop its blood screening strategy based on HBV endemicity, yields of infectious units detected by different serologic/NAT screening methods, and cost effectiveness of test methods in ensuring blood safety...
  90. ncbi The effects of early antiretroviral therapy and its discontinuation on the HIV-specific antibody response
    M Scott Killian
    Department of Medicine, University of California San Francisco, 94143, USA
    AIDS Res Hum Retroviruses 22:640-7. 2006
    ..These results demonstrate that early ART prevents the typical evolution of the HIV-1-specific antibody response and can alter the expected kinetics of this response in subjects discontinuing therapy...
  91. ncbi The impact of male-to-male sexual experience on risk profiles of blood donors
    Ana M Sanchez
    Westat, Rockville, Maryland 20850, USA
    Transfusion 45:404-13. 2005
    ..For donors with a more remote history of male-to-male sex, the findings were equivocal. A better understanding of the association between male-to-male sex and other UDRs appears needed...
  92. ncbi Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy
    Mary C Kuhns
    Abbott Laboratories, Abbott Park, Illinois, USA
    Transfusion 44:1332-9. 2004
    ..Studies showing a significant correlation between hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels have focused on the HBV seroconversion window period...
  93. ncbi Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing
    Susan L Stramer
    American Red Cross, Gaithersburg, MD, USA
    N Engl J Med 351:760-8. 2004
    ....
  94. ncbi Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection
    David M Asmuth
    Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA
    Antiviral Res 63:123-31. 2004
    ....
  95. ncbi Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000
    Fan Chen Tseng
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    Hepatology 46:666-71. 2007
    ..This decrease coincided with the implementation of prevention activities among this population...
  96. ncbi Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay
    Steven H Kleinman
    Westat, 1650 Research Boulevard, Rockville, MD 20850, USA
    Transfusion 47:1756-64. 2007
    ..Blood donor parvovirus B19 DNA prevalence with sensitive nucleic acid test assays has recently been demonstrated to be higher than that found with assays designed to detect high viral titers in the plasma manufacturing sector...
  97. ncbi Yield of hepatitis C virus nucleic acid testing among antibody-reactive or confirmed-positive samples
    Michael Schmidt
    Transfusion 45:1040-2. 2005
  98. ncbi Behavioral and infectious disease risks in young blood donors: implications for recruitment
    Mark A Damesyn
    Westat, Rockville, Maryland 20850-2062, USA
    Transfusion 43:1596-603. 2003
    ..The message not to donate when a behavioral risk is present or for obtaining HIV tests needs to be reinforced in younger donors...
  99. ncbi Utilization of follow-up specimens from viremic blood donors to assess the value of west nile virus immunoglobulin G avidity as an indicator of recent infection
    Harry E Prince
    Focus Diagnostics, Cypress, CA 90630, USA
    Clin Diagn Lab Immunol 12:1123-6. 2005
    ..Low avidity accurately indicated infection within the previous 4 months. However, due to rapid avidity maturation in some individuals, high avidity did not accurately indicate past infection...